COPENHAGEN, Feb 22 (Reuters) - Danish biotech drugmaker
Genmab's Darzalex, which is used to fight cancer in
bone marrow and marketed by Johnson & Johnson, has the
potential to achieve annual peak annual sales as high as $13
billion, its chief executive told Reuters.
Read more
No comments:
Post a Comment